OncLive SOSS

ELCC Updates in Immunotherapy and Beyond for Non–Small Cell Lung Cancer - Episode 8

Updates from ELCC: Advanced NSCLC and the EMPOWER-Lung1 Trial

May 16, 2023

Jarushka Naidoo, MD, M.B.B.Ch., Solange Peters, MD, PhD, Marina Chiara Garassino, MD

The panel reviews data presented at ELCC from EMPOWERLung1 investigating cemiplimab versus chemotherapy in patients with advanced NSCLC.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Overview of PD-L1 Testing in Advanced NSCLC

EP. 2: Subgrouping Patients with Advanced NSCLC for Tailored Treatment

EP. 3: CTLA-4 Targeted Regimens in Advanced NSCLC

EP. 4: Updates in Gender-Based Treatment for Patients with Advanced NSCLC

EP. 5: Data Updates on Single-Agent Immunotherapy in Advanced NSCLC

EP. 6: Updates from ELCC: Efficacy of Frontline Nivolumab + Ipilimumab in Metastatic Non-Squamous NSCLC

EP. 7: Updates from ELCC: 5-Year Update on Pembrolizumab vs Chemotherapy in Advanced NSCLC

EP. 8: Updates from ELCC: Advanced NSCLC and the EMPOWER-Lung1 Trial

EP. 9: Combination Chemotherapy and Immunotherapy for Advanced NSCLC

EP. 10: The Evolution of Chemoimmunotherapy in Advanced NSCLC

Sponsored in part by Regeneron. Content independently created by OncLive.

x